Home National Novartis Announces Positive Results For Phase 3 Trials of Cholesterol-reducing Drug

Novartis Announces Positive Results For Phase 3 Trials of Cholesterol-reducing Drug

by rajtamil
0 comment 37 views

novartis announces positive results for phase 3 trials of cholesterol-reducing drug

Swiss pharma company Novartis announced positive results from Leqvio – a cholesterol-lowering medication under phase 3 trials. According to the company’s statement, the drug has met its primary endpoints in the trial. “Leqvio monotherapy achieved clinically meaningful and statistically significant low-density lipoprotein cholesterol (LDL-C) lowering versus both placebo and ezetimibe in patients who were at low or moderate risk of developing atherosclerotic cardiovascular disease (ASCVD) and not receiving lipid-lowering therapy,” the company said in a statement.

According to Novartis, Leqvio is touted to be a standalone treatment for lowering cholesterol in patients at risk of ASCVD – a common condition that leads to cardiovascular diseases like coronary heart disease and peripheral arterial disease – when plaque builds up in the arteries, narrowing them and reducing blood flow to organs.

V-MONO is the first trial evaluating a small interfering RNA (siRNA) therapy taken as monotherapy to lower low-density lipoprotein. The company says it plans to present results from this trial at an upcoming medical meeting and share with regulatory agencies including the US Food and Drug Administration.

Related News | Study Says Poor Sleep Can Cause Weight Gain And Increase Cholesterol Levels

Study Says Poor Sleep Can Cause Weight Gain And Increase Cholesterol Levels

What Is The Difference Between A Bypass And An Open Heart Surgery?  Know Their Purpose And Dangerous Side Effects

What Is The Difference Between A Bypass And An Open Heart Surgery? Know Their Purpose And Dangerous Side Effects

Additionally, Novartis is also conducting several other studies, exploring Leqvio's use in both primary and secondary prevention of ASCVD. These studies aim to further solidify Leqvio's role in cholesterol management, with key results expected between 2024 and 2027.

According to news reports, VICTORION-1-PREVENT or V1P is the only dedicated study of a non-statin lipid-lowering therapy in a high-risk primary prevention population as defined by American College of Cardiology and American Heart Association guidelines; this outcomes study is expected to complete enrollment later this year.

Ways to keep cholesterol levels under control Related News | Signs Your Acidity May Be Heart Attack; Know Ways To Take Care Of Your Cardiovascular Health

Signs Your Acidity May Be Heart Attack; Know Ways To Take Care Of Your Cardiovascular Health

According to experts, a few natural strategies to keep your cholesterol levels in check, include:

Eat healthy

Doctors recommend choosing foods that are low in saturated and trans fats, sodium and added sugars. Incorporate more fruits, vegetables, and whole grains, and smaller amounts of eggs and lean poultry.

Exercise

According to the Department of Health and Human Services, adults must get at least 150-300 minutes of moderate-intensity or 75-150 minutes of vigorous-intensity aerobic exercise per week. You can spread this activity throughout the week, and you can start with lower-intensity activities and move to higher-intensity ones.

Quit smoking, alcohol

Both smoking and alcohol can be disastrous not just for your heart but overall health as well.

Manage stress

Several studies have said that stress can cause high cholesterol levels – which if not controlled can be detrimental to heart health and lead to life-threatening conditions like heart attack and stroke.

You may also like

2024 All Right Reserved.

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.